Lipigon Pharmaceuticals AB and Leaderna Therapeutics embarked on a strategic partnership to develop and commercialize Lipisense's drug candidate Lipisense, aimed at treating dyslipidemias such as severe hypertriglyceridemia (SHTG). This collaboration leverages the strengths of both companies to efficiently advance the clinical progress of Lipisense. Recently, Leaderna received approval to start a Phase I study in China.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.263 SEK | -4.71% |
|
-15.16% | -38.98% |
Chiffre d''affaires - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-38.98% | 3.3M | |
+55.95% | 811B | |
+43.62% | 640B | |
-6.98% | 353B | |
+19.08% | 333B | |
+9.05% | 302B | |
+16.30% | 246B | |
+2.41% | 225B | |
+12.47% | 218B | |
+8.91% | 168B |
- Stock Market
- Equities
- LPGO Stock
- News Lipigon Pharmaceuticals AB
- Lipigon Pharmaceuticals AB and Leaderna Therapeutics Collaboration on Lipisense® Shows Good Progress